呼吸器合胞体ウイルス（RSV）治療薬の世界市場（～2026年）

• 英文タイトル：Global Respiratory Syncytial Virus (RSV) Therapeutics Market Insights and Forecast to 2026

• レポートコード：MRC2-11QY09084 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は呼吸器合胞体ウイルス（RSV）治療薬のグローバル市場について調査・分析したレポートです。種類別（パリビズマブ、リバビリン、その他）市場規模、用途別（病院薬局、ドラッグストア、小売薬局、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別呼吸器合胞体ウイルス（RSV）治療薬の競争状況、市場シェア ・世界の呼吸器合胞体ウイルス（RSV）治療薬市場：種類別市場規模 2015年-2020年（パリビズマブ、リバビリン、その他） ・世界の呼吸器合胞体ウイルス（RSV）治療薬市場：種類別市場規模予測 2021年-2026年（パリビズマブ、リバビリン、その他） ・世界の呼吸器合胞体ウイルス（RSV）治療薬市場：用途別市場規模 2015年-2020年（病院薬局、ドラッグストア、小売薬局、その他） ・世界の呼吸器合胞体ウイルス（RSV）治療薬市場：用途別市場規模予測 2021年-2026年（病院薬局、ドラッグストア、小売薬局、その他） ・北米の呼吸器合胞体ウイルス（RSV）治療薬市場分析：米国、カナダ ・ヨーロッパの呼吸器合胞体ウイルス（RSV）治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの呼吸器合胞体ウイルス（RSV）治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の呼吸器合胞体ウイルス（RSV）治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの呼吸器合胞体ウイルス（RSV）治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Roche、AstraZeneca、Merck、AbbVie、Bausch Health、GlaxoSmithKline、ReViral、Gilead Sciences、Teva Pharmaceutical ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Market Analysis and Insights: Global Respiratory Syncytial Virus (RSV) Therapeutics Market
The global Respiratory Syncytial Virus (RSV) Therapeutics market size is projected to reach US$ 599.6 million by 2026, from US$ 564.7 million in 2020, at a CAGR of 5.7%% during 2021-2026.

Global Respiratory Syncytial Virus (RSV) Therapeutics Scope and Market Size
Respiratory Syncytial Virus (RSV) Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Respiratory Syncytial Virus (RSV) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Respiratory Syncytial Virus (RSV) Therapeutics market is segmented into
Palivizumab
Ribavirin
Others

Segment by Application, the Respiratory Syncytial Virus (RSV) Therapeutics market is segmented into
Hospital Pharmacies
Drug Stores
Retail Pharmacies
Others

Regional and Country-level Analysis
The Respiratory Syncytial Virus (RSV) Therapeutics market is analysed and market size information is provided by regions (countries).
The key regions covered in the Respiratory Syncytial Virus (RSV) Therapeutics market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Respiratory Syncytial Virus (RSV) Therapeutics Market Share Analysis
Respiratory Syncytial Virus (RSV) Therapeutics market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Respiratory Syncytial Virus (RSV) Therapeutics business, the date to enter into the Respiratory Syncytial Virus (RSV) Therapeutics market, Respiratory Syncytial Virus (RSV) Therapeutics product introduction, recent developments, etc.

The major vendors covered:
Roche
AstraZeneca
Merck
AbbVie
Bausch Health
GlaxoSmithKline
ReViral
Gilead Sciences
Teva Pharmaceutical

レポート目次

---

1 Study Coverage
1.1 Respiratory Syncytial Virus (RSV) Therapeutics Product Introduction
1.2 Market Segments
1.3 Key Respiratory Syncytial Virus (RSV) Therapeutics Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size Growth Rate by Type
1.4.2 Palivizumab
1.4.3 Ribavirin
1.4.4 Others
1.5 Market by Application
1.5.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size Growth Rate by Application
1.5.2 Hospital Pharmacies
1.5.3 Drug Stores
1.5.4 Retail Pharmacies
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Estimates and Forecasts
2.1.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue 2015-2026
2.1.2 Global Respiratory Syncytial Virus (RSV) Therapeutics Sales 2015-2026
2.2 Global Respiratory Syncytial Virus (RSV) Therapeutics, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Respiratory Syncytial Virus (RSV) Therapeutics Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Respiratory Syncytial Virus (RSV) Therapeutics Competitor Landscape by Players
3.1 Respiratory Syncytial Virus (RSV) Therapeutics Sales by Manufacturers
3.1.1 Respiratory Syncytial Virus (RSV) Therapeutics Sales by Manufacturers (2015-2020)
3.1.2 Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Manufacturers (2015-2020)
3.2 Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Manufacturers
3.2.1 Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Manufacturers (2015-2020)
3.2.2 Respiratory Syncytial Virus (RSV) Therapeutics Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Respiratory Syncytial Virus (RSV) Therapeutics Revenue in 2019
3.2.5 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Respiratory Syncytial Virus (RSV) Therapeutics Price by Manufacturers
3.4 Respiratory Syncytial Virus (RSV) Therapeutics Manufacturing Base Distribution, Product Types
3.4.1 Respiratory Syncytial Virus (RSV) Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Respiratory Syncytial Virus (RSV) Therapeutics Product Type
3.4.3 Date of International Manufacturers Enter into Respiratory Syncytial Virus (RSV) Therapeutics Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size by Type (2015-2020)
4.1.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Sales by Type (2015-2020)
4.1.2 Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Type (2015-2020)
4.1.3 Respiratory Syncytial Virus (RSV) Therapeutics Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast by Type (2021-2026)
4.2.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast by Type (2021-2026)
4.2.2 Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast by Type (2021-2026)
4.2.3 Respiratory Syncytial Virus (RSV) Therapeutics Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size by Application (2015-2020)
5.1.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Sales by Application (2015-2020)
5.1.2 Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Application (2015-2020)
5.1.3 Respiratory Syncytial Virus (RSV) Therapeutics Price by Application (2015-2020)
5.2 Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast by Application (2021-2026)
5.2.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast by Application (2021-2026)
5.2.2 Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast by Application (2021-2026)
5.2.3 Global Respiratory Syncytial Virus (RSV) Therapeutics Price Forecast by Application (2021-2026)

6 North America
6.1 North America Respiratory Syncytial Virus (RSV) Therapeutics by Country
6.1.1 North America Respiratory Syncytial Virus (RSV) Therapeutics Sales by Country
6.1.2 North America Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Type
6.3 North America Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Application

7 Europe
7.1 Europe Respiratory Syncytial Virus (RSV) Therapeutics by Country
7.1.1 Europe Respiratory Syncytial Virus (RSV) Therapeutics Sales by Country
7.1.2 Europe Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Type
7.3 Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics by Region
8.1.1 Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Sales by Region
8.1.2 Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Type
8.3 Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Application

9 Latin America
9.1 Latin America Respiratory Syncytial Virus (RSV) Therapeutics by Country
9.1.1 Latin America Respiratory Syncytial Virus (RSV) Therapeutics Sales by Country
9.1.2 Latin America Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Type
9.3 Central & South America Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics by Country
10.1.1 Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Sales by Country
10.1.2 Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Type
10.3 Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Application

11 Company Profiles
11.1 Roche
11.1.1 Roche Corporation Information
11.1.2 Roche Description and Business Overview
11.1.3 Roche Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Roche Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.1.5 Roche Related Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Corporation Information
11.2.2 AstraZeneca Description and Business Overview
11.2.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.2.4 AstraZeneca Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.2.5 AstraZeneca Related Developments
11.3 Merck
11.3.1 Merck Corporation Information
11.3.2 Merck Description and Business Overview
11.3.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Merck Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.3.5 Merck Related Developments
11.4 AbbVie
11.4.1 AbbVie Corporation Information
11.4.2 AbbVie Description and Business Overview
11.4.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
11.4.4 AbbVie Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.4.5 AbbVie Related Developments
11.5 Bausch Health
11.5.1 Bausch Health Corporation Information
11.5.2 Bausch Health Description and Business Overview
11.5.3 Bausch Health Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Bausch Health Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.5.5 Bausch Health Related Developments
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Corporation Information
11.6.2 GlaxoSmithKline Description and Business Overview
11.6.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.6.4 GlaxoSmithKline Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.6.5 GlaxoSmithKline Related Developments
11.7 ReViral
11.7.1 ReViral Corporation Information
11.7.2 ReViral Description and Business Overview
11.7.3 ReViral Sales, Revenue and Gross Margin (2015-2020)
11.7.4 ReViral Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.7.5 ReViral Related Developments
11.8 Gilead Sciences
11.8.1 Gilead Sciences Corporation Information
11.8.2 Gilead Sciences Description and Business Overview
11.8.3 Gilead Sciences Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Gilead Sciences Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.8.5 Gilead Sciences Related Developments
11.9 Teva Pharmaceutical
11.9.1 Teva Pharmaceutical Corporation Information
11.9.2 Teva Pharmaceutical Description and Business Overview
11.9.3 Teva Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Teva Pharmaceutical Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.9.5 Teva Pharmaceutical Related Developments
11.1 Roche
11.1.1 Roche Corporation Information
11.1.2 Roche Description and Business Overview
11.1.3 Roche Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Roche Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.1.5 Roche Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Respiratory Syncytial Virus (RSV) Therapeutics Market Estimates and Projections by Region
12.1.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast by Regions 2021-2026
12.1.2 Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast by Regions 2021-2026
12.2 North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast (2021-2026)
12.2.1 North America: Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast (2021-2026)
12.2.2 North America: Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast (2021-2026)
12.2.3 North America: Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast by Country (2021-2026)
12.3 Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast (2021-2026)
12.3.1 Europe: Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast (2021-2026)
12.3.2 Europe: Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast (2021-2026)
12.3.3 Europe: Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast by Region (2021-2026)
12.5 Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast (2021-2026)
12.5.1 Latin America: Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast (2021-2026)
12.5.2 Latin America: Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast (2021-2026)
12.5.3 Latin America: Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Respiratory Syncytial Virus (RSV) Therapeutics Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Respiratory Syncytial Virus (RSV) Therapeutics Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Respiratory Syncytial Virus (RSV) Therapeutics Market Segments
Table 2. Ranking of Global Top Respiratory Syncytial Virus (RSV) Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Palivizumab
Table 5. Major Manufacturers of Ribavirin
Table 6. Major Manufacturers of Others
Table 7. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size Growth Rate by Application 2020-2026 (K Units)
Table 8. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 9. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales by Regions 2015-2020 (K Units)
Table 10. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Regions (2015-2020)
Table 11. Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Regions 2015-2020 (US$ Million)
Table 12. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales by Manufacturers (2015-2020) (K Units)
Table 13. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Share by Manufacturers (2015-2020)
Table 14. Global Respiratory Syncytial Virus (RSV) Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 15. Global Respiratory Syncytial Virus (RSV) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Respiratory Syncytial Virus (RSV) Therapeutics as of 2019)
Table 16. Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Manufacturers (2015-2020) (US$ Million)
Table 17. Respiratory Syncytial Virus (RSV) Therapeutics Revenue Share by Manufacturers (2015-2020)
Table 18. Key Manufacturers Respiratory Syncytial Virus (RSV) Therapeutics Price (2015-2020) (USD/Unit)
Table 19. Respiratory Syncytial Virus (RSV) Therapeutics Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers Respiratory Syncytial Virus (RSV) Therapeutics Product Type
Table 21. Date of International Manufacturers Enter into Respiratory Syncytial Virus (RSV) Therapeutics Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales by Type (2015-2020) (K Units)
Table 24. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Share by Type (2015-2020)
Table 25. Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Type (2015-2020) (US$ Million)
Table 26. Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue Share by Type (2015-2020)
Table 27. Respiratory Syncytial Virus (RSV) Therapeutics Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 28. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales by Application (2015-2020) (K Units)
Table 29. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Share by Application (2015-2020)
Table 30. North America Respiratory Syncytial Virus (RSV) Therapeutics Sales by Country (2015-2020) (K Units)
Table 31. North America Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Country (2015-2020)
Table 32. North America Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 33. North America Respiratory Syncytial Virus (RSV) Therapeutics Revenue Market Share by Country (2015-2020)
Table 34. North America Respiratory Syncytial Virus (RSV) Therapeutics Sales by Type (2015-2020) (K Units)
Table 35. North America Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Type (2015-2020)
Table 36. North America Respiratory Syncytial Virus (RSV) Therapeutics Sales by Application (2015-2020) (K Units)
Table 37. North America Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Application (2015-2020)
Table 38. Europe Respiratory Syncytial Virus (RSV) Therapeutics Sales by Country (2015-2020) (K Units)
Table 39. Europe Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Country (2015-2020)
Table 40. Europe Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 41. Europe Respiratory Syncytial Virus (RSV) Therapeutics Revenue Market Share by Country (2015-2020)
Table 42. Europe Respiratory Syncytial Virus (RSV) Therapeutics Sales by Type (2015-2020) (K Units)
Table 43. Europe Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Type (2015-2020)
Table 44. Europe Respiratory Syncytial Virus (RSV) Therapeutics Sales by Application (2015-2020) (K Units)
Table 45. Europe Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Application (2015-2020)
Table 46. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Sales by Region (2015-2020) (K Units)
Table 47. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Region (2015-2020)
Table 48. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Region (2015-2020) (US$ Million)
Table 49. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Revenue Market Share by Region (2015-2020)
Table 50. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Sales by Type (2015-2020) (K Units)
Table 51. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Type (2015-2020)
Table 52. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Sales by Application (2015-2020) (K Units)
Table 53. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Application (2015-2020)
Table 54. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Sales by Country (2015-2020) (K Units)
Table 55. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Country (2015-2020)
Table 56. Latin Americaa Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 57. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Revenue Market Share by Country (2015-2020)
Table 58. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Sales by Type (2015-2020) (K Units)
Table 59. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Type (2015-2020)
Table 60. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Sales by Application (2015-2020) (K Units)
Table 61. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Application (2015-2020)
Table 62. Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Sales by Country (2015-2020) (K Units)
Table 63. Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Country (2015-2020)
Table 64. Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 65. Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Revenue Market Share by Country (2015-2020)
Table 66. Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Sales by Type (2015-2020) (K Units)
Table 67. Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Type (2015-2020)
Table 68. Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Sales by Application (2015-2020) (K Units)
Table 69. Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Application (2015-2020)
Table 70. Roche Corporation Information
Table 71. Roche Description and Major Businesses
Table 72. Roche Respiratory Syncytial Virus (RSV) Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 73. Roche Product
Table 74. Roche Recent Development
Table 75. AstraZeneca Corporation Information
Table 76. AstraZeneca Description and Major Businesses
Table 77. AstraZeneca Respiratory Syncytial Virus (RSV) Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 78. AstraZeneca Product
Table 79. AstraZeneca Recent Development
Table 80. Merck Corporation Information
Table 81. Merck Description and Major Businesses
Table 82. Merck Respiratory Syncytial Virus (RSV) Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 83. Merck Product
Table 84. Merck Recent Development
Table 85. AbbVie Corporation Information
Table 86. AbbVie Description and Major Businesses
Table 87. AbbVie Respiratory Syncytial Virus (RSV) Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 88. AbbVie Product
Table 89. AbbVie Recent Development
Table 90. Bausch Health Corporation Information
Table 91. Bausch Health Description and Major Businesses
Table 92. Bausch Health Respiratory Syncytial Virus (RSV) Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 93. Bausch Health Product
Table 94. Bausch Health Recent Development
Table 95. GlaxoSmithKline Corporation Information
Table 96. GlaxoSmithKline Description and Major Businesses
Table 97. GlaxoSmithKline Respiratory Syncytial Virus (RSV) Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 98. GlaxoSmithKline Product
Table 99. GlaxoSmithKline Recent Development
Table 100. ReViral Corporation Information
Table 101. ReViral Description and Major Businesses
Table 102. ReViral Respiratory Syncytial Virus (RSV) Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 103. ReViral Product
Table 104. ReViral Recent Development
Table 105. Gilead Sciences Corporation Information
Table 106. Gilead Sciences Description and Major Businesses
Table 107. Gilead Sciences Respiratory Syncytial Virus (RSV) Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 108. Gilead Sciences Product
Table 109. Gilead Sciences Recent Development
Table 110. Teva Pharmaceutical Corporation Information
Table 111. Teva Pharmaceutical Description and Major Businesses
Table 112. Teva Pharmaceutical Respiratory Syncytial Virus (RSV) Therapeutics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 113. Teva Pharmaceutical Product
Table 114. Teva Pharmaceutical Recent Development
Table 115. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast by Regions (2021-2026) (K Units)
Table 116. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share Forecast by Regions (2021-2026)
Table 117. Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 118. Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue Market Share Forecast by Regions (2021-2026)
Table 119. North America: Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast by Country (2021-2026) (K Units)
Table 120. North America: Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 121. Europe: Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast by Country (2021-2026) (K Units)
Table 122. Europe: Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 123. Asia Pacific: Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast by Region (2021-2026) (K Units)
Table 124. Asia Pacific: Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast by Region (2021-2026) (US$ Million)
Table 125. Latin America: Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast by Country (2021-2026) (K Units)
Table 126. Latin America: Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 127. Middle East and Africa: Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast by Country (2021-2026) (K Units)
Table 128. Middle East and Africa: Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 129. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 130. Key Challenges
Table 131. Market Risks
Table 132. Main Points Interviewed from Key Respiratory Syncytial Virus (RSV) Therapeutics Players
Table 133. Respiratory Syncytial Virus (RSV) Therapeutics Customers List
Table 134. Respiratory Syncytial Virus (RSV) Therapeutics Distributors List
Table 135. Research Programs/Design for This Report
Table 136. Key Data Information from Secondary Sources
Table 137. Key Data Information from Primary Sources
List of Figures
Figure 1. Respiratory Syncytial Virus (RSV) Therapeutics Product Picture
Figure 2. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Type in 2020 & 2026
Figure 3. Palivizumab Product Picture
Figure 4. Ribavirin Product Picture
Figure 5. Others Product Picture
Figure 6. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Application in 2020 & 2026
Figure 7. Hospital Pharmacies
Figure 8. Drug Stores
Figure 9. Retail Pharmacies
Figure 10. Others
Figure 11. Respiratory Syncytial Virus (RSV) Therapeutics Report Years Considered
Figure 12. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size 2015-2026 (US$ Million)
Figure 13. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales 2015-2026 (K Units)
Figure 14. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Region (2015-2020)
Figure 16. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Region in 2019
Figure 17. Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue Market Share by Region (2015-2020)
Figure 18. Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue Market Share by Region in 2019
Figure 19. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Respiratory Syncytial Virus (RSV) Therapeutics Revenue in 2019
Figure 21. Respiratory Syncytial Virus (RSV) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Type (2015-2020)
Figure 23. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Type in 2019
Figure 24. Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue Market Share by Type (2015-2020)
Figure 25. Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue Market Share by Type in 2019
Figure 26. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Share by Price Range (2015-2020)
Figure 27. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Application (2015-2020)
Figure 28. Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Application in 2019
Figure 29. Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue Market Share by Application (2015-2020)
Figure 30. Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue Market Share by Application in 2019
Figure 31. North America Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate 2015-2020 (K Units)
Figure 32. North America Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Country in 2019
Figure 34. North America Respiratory Syncytial Virus (RSV) Therapeutics Revenue Market Share by Country in 2019
Figure 35. U.S. Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 36. U.S. Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 38. Canada Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Respiratory Syncytial Virus (RSV) Therapeutics Market Share by Type in 2019
Figure 40. North America Respiratory Syncytial Virus (RSV) Therapeutics Market Share by Application in 2019
Figure 41. Europe Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate 2015-2020 (K Units)
Figure 42. Europe Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Country in 2019
Figure 44. Europe Respiratory Syncytial Virus (RSV) Therapeutics Revenue Market Share by Country in 2019
Figure 45. Germany Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 46. Germany Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 48. France Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 50. U.K. Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 52. Italy Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 54. Russia Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Share by Type in 2019
Figure 56. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Share by Application in 2019
Figure 57. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate 2015-2020 (K Units)
Figure 58. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Region in 2019
Figure 60. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Revenue Market Share by Region in 2019
Figure 61. China Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 62. China Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 64. Japan Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 66. South Korea Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 68. India Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 70. Australia Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 72. Taiwan Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 74. Indonesia Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 76. Thailand Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 78. Malaysia Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 80. Philippines Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 82. Vietnam Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Share by Type in 2019
Figure 84. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Share by Application in 2019
Figure 85. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate 2015-2020 (K Units)
Figure 86. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Country in 2019
Figure 88. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Revenue Market Share by Country in 2019
Figure 89. Mexico Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 90. Mexico Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 92. Brazil Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 94. Argentina Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Share by Type in 2019
Figure 96. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Share by Application in 2019
Figure 97. Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate 2015-2020 (K Units)
Figure 98. Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Revenue Market Share by Country in 2019
Figure 101. Turkey Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 102. Turkey Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 104. Saudi Arabia Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate (2015-2020) (K Units)
Figure 106. U.A.E Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Share by Type in 2019
Figure 108. Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Share by Application in 2019
Figure 109. North America Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 110. North America Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 112. Europe Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 114. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 116. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 118. Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed

---